J Intern Med. And, if so, why? The epidemiological evidence. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Part II. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.
Acta Neuropathol. J Neuropathol Exp Neurol. Am J Pathol. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med. Ageing and dementia. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. Neuropathological comparisons of amnestic and nonamnestic mild cognitive impairment. BMC Neurol.
Cytokine receptor family | Catalytic receptors | IUPHAR/BPS Guide to PHARMACOLOGY
Markesbery WR. Neuropathologic alterations in mild cognitive impairment: a review. Cytokine gene expression as a function of the clinical progression of Alzheimer disease dementia. Alzheimer Dis Assoc Disord. Factors associated with resistance to dementia despite high Alzheimer disease pathology. Neuropathology of cognitively normal elderly.
Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls. The cholinergic deficit coincides with Abeta deposition at the earliest histopathologic stages of Alzheimer disease. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques.
Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease-a brief review of the basic science and clinical literature. Interleukin a master regulator of neuroinflammation. J Neurosci Res.
Liu L, Chan C. Ageing Res Rev. J Neuroinflammation. Curr Pharm Des. Mol Psychiatry. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. IL alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Il10 deficiency rebalances innate immunity to mitigate Alzheimerlike pathology.
J Neuroimmunol. Avicenna J Med Biotechnol. Eur J Neurosci. The Sun Health Research Institute brain donation program: description and experience, — Cell Tissue Bank. Beta-secretase activity increases with aging in human, monkey, and mouse brain. Acta Neuropathologica. Biochem Biophys Res Commun. Regional differences in blood-brain barrier permeability changes and inflammation in the apathogenic clearance of virus from the central nervous system.
J Immunol. Cell Death Dis. Brain Res. Differential expression of individual complement regulators in the brain and choroid plexus. Lab Invest.
- Marriage and Slavery in Early Islam.
- Cytokines as Potential Therapeutic Targets for Inflammatory Skin Diseases: 56 (Ernst Schering Foundation Symposium Proceedings).
- Interleukin-6, a Major Cytokine in the Central Nervous System.
- Dawns Awakening (Breed Book 14)!
The expression of CD59 in normal human nervous tissue. J Neurosci. Complement-mediated neurotoxicity is regulated by homologous restriction. Complement regulators C1 inhibitor and CD59 do not significantly inhibit complement activation in Alzheimer disease. Front Endocrinol Lausanne ; 7 Curr Alzheimer Res. Glucocorticoids increase excitotoxic injury and inflammation in the hippocampus of adult male rats.
Glucocorticoids exacerbate lipopolysaccharide-induced signaling in the frontal cortex and hippocampus in a dose-dependent manner. Stress increases vulnerability to inflammation in the rat prefrontal cortex. The stressed CNS: when glucocorticoids aggravate inflammation. Novel glucocorticoid effects on acute inflammation in the CNS. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
BMC Neurosci. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Nonsteroidal anti-inflammatory drugs are associated with increased neuritic plaques. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.
Am J Geriatr Psychiatry. Frautschy SA. Neurobiol Dis. Cyclooxygenase-2 inhibition improves amyloid-beta-mediated suppression of memory and synaptic plasticity. Moon JH. Endocrine Risk Factors for Cognitive Impairment. Endocrinol Metab Seoul ; 31 — Front Aging Neurosci.
Memory impairments in healthy aging: Role of aging-induced microglial sensitization. Aging Dis. Metabolic syndrome, insulin resistance, and roles of inflammation - Mechanisms and therapeutic targets. Arterioscler Thromb Vasc Biol. Yarchoan M, Arnold SE.
Physiological potential of cytokines and liver damages
Repurposing diabetes drugs for brain insulin resistance in Alzheimer disease. Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo. Insulin receptor signaling in long-term memory consolidation following spatial learning. Learn Mem. Cell Metab. CNS Neurosci Ther. Tobinick E. Chronic neuron-specific tumor necrosis factor-a expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTG-AD mice.
Differential effects of oligomeric and fibrillar amyloid-beta 1—42 on astrocyte-mediated inflammation. Tumor necrosis factor-alpha mediated signaling in neuronal homeostasis and dysfunction. Cell Signal. CNS Drugs. Rapid tumor necrosis factor a-induced exocytosis of glutamate receptor 2-lacking AMPA receptors to extrasynaptic plasma membrane potentiates excitotoxicity.
J Cell Biol. Hippocampal expression of murine TNFa results in attenuation of amyloid deposition in vivo. Biochim Biophys Acta. Tumor necrosis factors protect neurons against metabolic-excitotoxic insults and promote maintenance of calcium homeostasis. Age-related changes to tumor necrosis factor receptors affect neuron survival in the presence of beta-amyloid.
Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discov. Tumor necrosis factor signaling. Cell Death Differ. Snider, W. Tackling pain at the source: new ideas about nociceptors. Neuron 20 , — Tsuda, M.
Microglia in the spinal cord and neuropathic pain. Diabetes Invest. P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Sorge, R. Different immune cells mediate mechanical pain hypersensitivity in male and female mice. Immunity 16 , — Naik, S. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Sprecher, C. Cloning and characterization of a novel class I cytokine receptor.
Wolf, G. Impairment of interleukin-1 IL-1 signaling reduces basal pain sensitivity in mice: genetic, pharmacological and developmental aspects. Pain , — Xu, X. Nociceptive responses in interleukindeficient mice to peripheral inflammation and peripheral nerve section. Uceyler, N. IL-4 deficiency is associated with mechanical hypersensitivity in mice. Vanderwall, A. Effects of spinal non-viral interleukin gene therapy formulated with d-mannose in neuropathic interleukin deficient mice: Behavioral characterization, mRNA and protein analysis in pain relevant tissues.
Brain Behav. Andratsch, M. A key role for gp expressed on peripheral sensory nerves in pathological pain. McNamara, C. TRPA1 mediates formalin-induced pain. Wang, S. Zeitvogel, J. Human primary keratinocytes show restricted ability to up-regulate suppressor of cytokine signaling SOCS 3 protein compared with autologous macrophages. Riol-Blanco, L. Nociceptive sensory neurons drive interleukinmediated psoriasiform skin inflammation. Tsutsumi, M. Mechanical-stimulation-evoked calcium waves in proliferating and differentiated human keratinocytes.
Cell Tissue Res. Mandadi, S. Pflugers Arch. Mihara, H. Fell, G. Skin beta-endorphin mediates addiction to UV light. Baumbauer, K. Keratinocytes can modulate and directly initiate nociceptive responses. Moehring, F. Zimmermann, M. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16 , — WSX-1 is required for the initiation of Th1 responses and resistance to L. Immunity 15 , — Igawa, T. Kimura, D. Flatters, S. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Behavioral phenotypes of mice lacking purinergic P2X4 receptors in acute and chronic pain assays.
Chaplan, S. Quantitative assessment of tactile allodynia in the rat paw. Sakurada, T. Antinociceptive effects in the formalin and capsaicin tests after intrathecal administration of substance P analogues in mice. Hunskaar, S. Formalin test in mice, a useful technique for evaluating mild analgesics. Tjolsen, A. The formalin test: an evaluation of the method. Pain 51 , 5—17 The capsaicin test in mice for evaluating tachykinin antagonists in the spinal cord. Neuropharmacology 31 , — Evidence for the involvement of spinal endogenous ATP and P2X receptors in nociceptive responses caused by formalin and capsaicin in mice.
Kim, S. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50 , — Goldberg, R. Suppression of ongoing adjuvant-induced arthritis by neutralizing the function of the p28 subunit of IL Zhao, X. Neutrophil polarization by IL as a therapeutic target for intracerebral hemorrhage.
Bosmann, M. Reeh, P. Sensory receptors in mammalian skin in an in vitro preparation.
Zimmermann, K. Phenotyping sensory nerve endings in vitro in the mouse. Taguchi, T. Cutaneous C-fiber nociceptor responses and nociceptive behaviors in aged Sprague-Dawley rats. Download references. We are grateful to Dr. Miyake, T. Yamashita, Mr. Yamamoto, and Mr. Tashima for expert technical assistance. We thank Mr. Ono and Y. Kitayama for assistance with the experiments. All authors reviewed the manuscript. Correspondence to Hiroki Yoshida or Toshiharu Yasaka. Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Reprints and Permissions. By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Advanced search. Skip to main content. Subjects Chronic pain Neuroimmunology Sensory processing. Abstract Numerous studies have shown that pain sensation is affected by various immune molecules, such as cytokines, in tissues comprising the sensory pathway. Introduction Chronic pain is defined as pain that lasts over three months.
Figure 1. Full size image. Figure 2. Figure 3. Figure 4. Figure 5. Behavioural assessments Thermal sensitivity To assess sensitivity to heat, we conducted the hot-plate and tail-flick tests. Mechanical sensitivity To assess mechanical sensitivity, mice were placed individually in a transparent glass cylinder and separated from each other by an opaque divider, which was placed on a wire mesh. Formalin-induced nociceptive behaviours The procedure used for the formalin test has been described elsewhere 54 , 56 , Your Email:. Colleague's Email:.
Separate multiple e-mails with a ;. Thought you might appreciate this item s I saw at Medicine. Send a copy to your email. Some error has occurred while processing your request. Please try after some time. Back to Top Article Outline. TABLE 1. TABLE 2. TABLE 3. TABLE 4. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol ; — Cited Here Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.
Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies.
- Biological Nanostructures and Applications of Nanostructures in Biology : Electrical, Mechanical, and Optical Properties (Bioelectric Engineering).
- Featured Cytokines.
Scand J Gastroenterol ; — Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.
Clin Gastroenterol Hepatol ; — Antibody response to infliximab and its impact on pharmacokinetics can be transient. Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut ; — Individualized therapy is a long-term cost-effective method compared to dose intensification in Crohn's disease patients failing infliximab. Dig Dis Sci ; — PubMed CrossRef. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
Yanai H, lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Implications of infliximab treatment failure and influence of personalized treatment on patient-reported health-related quality of life and productivity outcomes in Crohn's disease. J Crohns Colitis ; — Ben-Horin S, Chowers Y.
Nat Rev Gastroenterol Hepatol ; — Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease IBD : a meta-analysis. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Gastroenterology ; — Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis.
Therapeutic drug monitoring of anti-tumor necrosis factor agents in patients with inflammatory bowel diseases. Inflamm Bowel Dis ; — New insights into the mechanisms of action of anti-tumor necrosis factor-alpha monoclonal antibodies in inflammatory bowel disease. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease.
Changes in serum trough levels of infliximab during treatment intensification but not in anti-infliximab antibody detection are associated with clinical outcomes after therapeutic failure in Crohn's disease.